🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in France / NCT04224064
Recruiting Not applicable

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

NCT04224064 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2020-08-26
Last updated
2025-02-12

Condition(s) studied

LiposarcomaAtypical Lipomatous Tumor

Investigational drug(s) / intervention(s)

Blood sampling

Blood sampling: Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.

Study summary

The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria for LPS patients cohort: Men/women older than 18 years old, Surgery for : * Localized WD-LPS and DD-LPS, and/or * WD-LPS or DD-LPS local relapse, and/or * WD-LPS or DD-LPS distant relapse and/or * Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent Inclusion Criteria for healthy subjects cohort: Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort Exclusion Criteria: Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma. Pregnancy and/or feeding

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institut du Cancer de Montpellier - Val d'Aurelle Montpellier France Recruiting

More Institut du Cancer de Montpellier - Val d'Aurelle trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04224064 on ClinicalTrials.gov ↗ ← All trials in France